3-[6-(6-methy-5-methy-piridin-3-il)-5,6,7,8-tetrahydro-pirido[4,3-d]pirimidin-4-iloxi]-pirrolidin-1-il-(tetrahydrolidin-piran-4-il) -methane, salt； pharmacological synthesis； used in the treatment of autoimmune disorders, inflammation Heart disease, allergies, rejection of transplants, etc.
HOGENAUER KLEMENS,HOLLINGWORTH GREGORY,SOLDERMANN NICOLAS,STOWASSER FRANK,TUFILLI NICOLAS,ZECRI FREDERIC,FERNANDES GOMES DOS SANTOS PAULO ANTONIO
申请号：
CL2013003567
公开号：
CL2013003567A1
申请日:
2013.12.12
申请国别(地区):
CL
年份:
2014
代理人:
摘要：
The invention relates to crystalline anhydrous forms, crystalline solvate forms and/or salt forms including crystalline salt forms of {(S)-3-[6-(6-methoxy-5-methyl-pyridin-3-yl)-5,6,7,8- tetrahydro-pyrido[4,3-d]pyrimidin-4-yloxy]-pyrrolidin-1-yl}-(tetrahydro-pyran-4-yl)-methanone or salt forms including crystalline salt forms of 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl- pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-on； pharmaceutical compositions and combinations including these forms as well as to methods of using these forms, including their pharmaceutical compositions and combinations for the treatment of diseases.FORMA CRISTALINA ANHIDRA DE {(S)-3-[6-(6-METOXI-5-METIL-PIRIDIN-3-IL)-5,6,7,8-TETRAHIDRO-PIRIDO[4,3-D]PIRIMIDIN-4-ILOXI]-PIRROLIDIN-1-IL}-(TETRAHIDRO-PIRAN-4-IL)-METANONA, SALES DE LA MISMA； COMPOSICION FARMACEUTICA； COMBINACION FARMACEUTICA； USO EN EL TRATAMIENTO DE TRASTORNOS AUTOINMUNES, INFLAMATORIOS, ALERGICOS, RECHAZO DE TRASPLANTES, ENTRE OTROS.
